Literature DB >> 11074743

Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.

M M Ward1.   

Abstract

BACKGROUND: The availability of more effective treatments for severe lupus nephritis may have influenced the rate at which end-stage renal disease (ESRD) develops in these patients.
OBJECTIVE: To examine changes in the incidence of ESRD due to lupus nephritis from 1982 to 1995.
METHODS: All patients with incident ESRD included in the US Renal Data System from 1982 to 1995 were studied. The US Renal Data System includes information on all patients who receive Medicare-reimbursed renal replacement therapy, who constitute approximately 94% of all patients with ESRD in the United States. The incidence of ESRD due to lupus nephritis in each year, standardized to the age-sex-ethnicity composition of the US general population in 1990, was computed in this serial cross-sectional study.
RESULTS: The standardized incidence rate of ESRD due to lupus nephritis increased steadily from 1.16 cases per million person-years in 1982 to 3.08 cases per million person-years in 1995. The rate of increase was comparable to that of ESRD due to all other primary renal diseases.
CONCLUSION: The incidence of ESRD due to lupus nephritis increased steadily over the 14-year study period, despite the introduction of efficacious new treatment regimens for lupus nephritis during this time.

Entities:  

Mesh:

Year:  2000        PMID: 11074743     DOI: 10.1001/archinte.160.20.3136

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  31 in total

1.  Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.

Authors:  Adnan N Kiani; Tianfu Wu; Hong Fang; Xin J Zhou; Chul W Ahn; Laurence S Magder; Chandra Mohan; Michelle Petri
Journal:  J Rheumatol       Date:  2012-04-15       Impact factor: 4.666

2.  Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Authors:  Celine C Berthier; Ramalingam Bethunaickan; Tania Gonzalez-Rivera; Viji Nair; Meera Ramanujam; Weijia Zhang; Erwin P Bottinger; Stephan Segerer; Maja Lindenmeyer; Clemens D Cohen; Anne Davidson; Matthias Kretzler
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

3.  Conference report--lupus nephritis: diagnosis, therapy, and outcomes.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-07-02

4.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

5.  IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.

Authors:  Marta E Stremska; Chao Dai; Rajkumar Venkatadri; Hongyang Wang; Vikram Sabapathy; Gaurav Kumar; Sheethal Jose; Saleh Mohammad; Sun-Sang J Sung; Shu Man Fu; Rahul Sharma
Journal:  J Autoimmun       Date:  2019-05-15       Impact factor: 7.094

6.  Connective tissue diseases: Lupus nephritis-winning a few battles but not the war.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2011-06-21       Impact factor: 20.543

Review 7.  Why targeted therapies are necessary for systemic lupus erythematosus.

Authors:  L Durcan; M Petri
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

8.  Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy.

Authors:  Fei Gu; Dandan Wang; Huayong Zhang; Xuebing Feng; Gary S Gilkeson; Songtao Shi; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-08-14       Impact factor: 2.980

9.  After 4 Decades of Lupus Nephritis Trials, Is There a "Best" Therapy?

Authors:  Andrew S Bomback
Journal:  Am J Kidney Dis       Date:  2017-09       Impact factor: 8.860

Review 10.  Kidney transplantation in patients with systemic lupus erythematosus.

Authors:  Sophia Lionaki; Chrysanthi Skalioti; John N Boletis
Journal:  World J Transplant       Date:  2014-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.